摘要: For several years, molecular imaging with 18F-fluorodeoxyglucose positron emission tomography (FDG-PET) has become part of the standard care in presurgical staging patients non-small-cell lung cancer (NSCLC), focusing on detection malignant lesions at early stages, recurrence and metastatic spread. Currently, there is an increasing interest role FDG-PET beyond staging, such as evaluation biological characteristics tumor prediction prognosis context treatment stratification assessment response to therapy. In this systematic review, literature value evolving applications a marker for (i.e. therapy monitoring) NSCLC addressed, divided sections predictive locally advanced disease, prognostic diagnosis, after induction recurrent disease. Furthermore, background recommendations application these indications will be discussed.